These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 36599002)

  • 21. Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients.
    Duan D
    Hum Gene Ther; 2018 Jul; 29(7):733-736. PubMed ID: 29463117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspective on Adeno-Associated Virus Capsid Modification for Duchenne Muscular Dystrophy Gene Therapy.
    Nance ME; Duan D
    Hum Gene Ther; 2015 Dec; 26(12):786-800. PubMed ID: 26414293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene Therapy for Duchenne Muscular Dystrophy.
    Elangkovan N; Dickson G
    J Neuromuscul Dis; 2021; 8(s2):S303-S316. PubMed ID: 34511510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression.
    Wang Z; Kuhr CS; Allen JM; Blankinship M; Gregorevic P; Chamberlain JS; Tapscott SJ; Storb R
    Mol Ther; 2007 Jun; 15(6):1160-6. PubMed ID: 17426713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dystrophin Gene-Editing Stability Is Dependent on Dystrophin Levels in Skeletal but Not Cardiac Muscles.
    Bengtsson NE; Tasfaout H; Hauschka SD; Chamberlain JS
    Mol Ther; 2021 Mar; 29(3):1070-1085. PubMed ID: 33160075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin.
    Vieira NM; Valadares M; Zucconi E; Secco M; Bueno CR; Brandalise V; Assoni A; Gomes J; Landini V; Andrade T; Caetano HV; Vainzof M; Zatz M
    Cell Transplant; 2012; 21(7):1407-17. PubMed ID: 23168016
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of Immunomodulatory Treatments on Anti-Dystrophin Immune Response After AAV Gene Therapy in Dystrophin Deficient mdx Mice.
    Li N; Parkes JE; Spathis R; Morales M; Mcdonald J; Kendra RM; Ott EM; Brown KJ; Lawlor MW; Nagaraju K
    J Neuromuscul Dis; 2021; 8(s2):S325-S340. PubMed ID: 34569971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping.
    Vulin A; Barthélémy I; Goyenvalle A; Thibaud JL; Beley C; Griffith G; Benchaouir R; le Hir M; Unterfinger Y; Lorain S; Dreyfus P; Voit T; Carlier P; Blot S; Garcia L
    Mol Ther; 2012 Nov; 20(11):2120-33. PubMed ID: 22968479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR
    J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
    Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
    Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy.
    Barbash IM; Cecchini S; Faranesh AZ; Virag T; Li L; Yang Y; Hoyt RF; Kornegay JN; Bogan JR; Garcia L; Lederman RJ; Kotin RM
    Gene Ther; 2013 Mar; 20(3):274-82. PubMed ID: 22551778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
    Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
    Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A canine minidystrophin is functional and therapeutic in mdx mice.
    Wang B; Li J; Qiao C; Chen C; Hu P; Zhu X; Zhou L; Bogan J; Kornegay J; Xiao X
    Gene Ther; 2008 Aug; 15(15):1099-106. PubMed ID: 18432277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Gene therapy for muscular dystrophy].
    Takeda S
    No To Hattatsu; 2004 Mar; 36(2):117-23. PubMed ID: 15031985
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
    Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
    BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance.
    Hayashita-Kinoh H; Yugeta N; Okada H; Nitahara-Kasahara Y; Chiyo T; Okada T; Takeda S
    Mol Ther; 2015 Apr; 23(4):627-37. PubMed ID: 25586688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential limitations of microdystrophin gene therapy for Duchenne muscular dystrophy.
    Hart CC; Lee YI; Xie J; Gao G; Lin BL; Hammers DW; Sweeney HL
    JCI Insight; 2024 May; 9(11):. PubMed ID: 38713520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro assay for the efficacy assessment of AAV vectors expressing microdystrophin.
    Danilov KA; Vassilieva SG; Polikarpova AV; Starikova AV; Shmidt AA; Galkin II; Tsitrina AA; Egorova TV; Orlov SN; Kotelevtsev YV
    Exp Cell Res; 2020 Jul; 392(2):112033. PubMed ID: 32360435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of Therapeutic Potential of a Dual AAV Approach for Duchenne Muscular Dystrophy.
    Albini S; Palmieri L; Dubois A; Bourg N; Lostal W; Richard I
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.